Published on 17 Apr 2023 on Simply Wall St. via Yahoo Finance

There's No Escaping Paratek Pharmaceuticals, Inc.'s (NASDAQ:PRTK) Muted Revenues Despite A 77% Share...

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) shareholders would be excited to see that the share price has had a great month, posting a 77% gain and recovering from prior weakness. Taking a wider view, although not as strong as the last month, the full year gain of 16% is also fairly reasonable.

In spite of the firm bounce in price, Paratek Pharmaceuticals may still look like a strong buying opportunity at present with its price-to-sales (or "P/S") ratio of 1x, considering almost half of all companies in the Pharmaceuticals industry in the United States have P/S ratios greater than 3.1x and even P/S higher than 15x aren't out of the ordinary. Nonetheless, we'd need to dig a little deeper to determine if there is a rational basis for the highly reduced P/S.

View our latest analysis for Paratek Pharmaceuticals